Contribution of new immunoglobulin-derived biomarkers in plasma cell dyscrasias and lymphoproliferative disorders

doi:10.5315/wjh.v2.i2.6

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5078)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

422

HTML

2885

Figures (1-4)

149

Sum=3456

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

957

Download

665

Sum=1622

May 6, 2013 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hematology

ISSN

2218-6204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hematol. May 6, 2013; 2(2): 6-12
Published online May 6, 2013. doi: 10.5315/wjh.v2.i2.6

Full Size Figure Download Figure

Figure 1 Estimated importance of additional information provided by free κ and λ free light chains for the diagnosis, prognosis, evaluation of response and monitoring of multiple myeloma, monoclonal gammopathy of undetermined significance, amyloid light-chain amyloidosis, chronic lymphocytic leukemia, non-Hodgkin lymphomas and Waldenstroms’ macroglobulinemia. MM: Multiple myeloma; MGUS: Monoclonal gammopathy of undetermined significance; CLL: Chronic lymphocytic leukemia; B-NHL: B-cell non-Hodgkin lymphomas; WM: Waldenstroms’ macroglobulinemia; AL: Amyloid light-chain.

Citation: Kyrtsonis MC, Maltezas D, Koulieris E, Tzenou T, Harding SJ. Contribution of new immunoglobulin-derived biomarkers in plasma cell dyscrasias and lymphoproliferative disorders. World J Hematol 2013; 2(2): 6-12
URL: https://www.wjgnet.com/2218-6204/full/v2/i2/6.htm
DOI: https://dx.doi.org/10.5315/wjh.v2.i2.6